問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2020-07-22 - 2025-11-30
Condition/Disease
Test Drug
Participate Sites7Sites
Recruiting7Sites
2022-05-24 - 2028-06-30
Participate Sites5Sites
Not yet recruiting5Sites
2022-03-01 - 2024-09-30
Participate Sites2Sites
Recruiting2Sites
2021-05-18 - 2023-12-31
Participate Sites10Sites
Terminated10Sites
2021-12-27 - 2024-07-10
Terminated5Sites
2024-02-16 - 2027-06-08
Participate Sites4Sites
Not yet recruiting1Sites
Recruiting3Sites
2019-09-15 - 2027-05-31
Participate Sites8Sites
Recruiting8Sites
2025-02-28 - 2032-06-30
Early breast cancer that is lymph node–positive, estrogen receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative, with a high risk of recurrence.
Elacestrant
Participate Sites13Sites
Recruiting13Sites
2022-11-30 - 2028-12-31
Colitis, Ulcerative
GuselkumabGolimumabJNJ-78934804
Participate Sites6Sites
Recruiting1Sites
2025-04-01 - 2028-08-31
Recruiting4Sites
全部
